Month: February 2025

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 months Full clinical and translational data for rosnilimab in RA in Q2 2025 Top-line Phase 2 data for rosnilimab in ulcerative colitis (UC), moved up to Q4 2025 Phase 1a trial in healthy volunteers ongoing for ANB033, our CD122 antagonist, and Phase 1a trial to initiate this quarter for ANB101, our BDCA2 modulator Announced exclusive global license agreement with Vanda Pharmaceuticals to develop and commercialize imsidolimab, an IL-36R antagonist Year-end 2024 cash and investments of ~$420 million and reiterating cash runway through year-end 2027SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company...

MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) — CubeSmart (NYSE: CUBE) today announced its operating results for the three and twelve months ended December 31, 2024. “Operating trends in the quarter were in line with our expectations given the volatile self-storage environment,” commented President and Chief Executive Officer Christopher P. Marr. “Looking forward to 2025, we are optimistic that we have reached an inflection point in the trend of decelerating growth rates, although we remain cautious given the macro uncertainty. Our expectation is that self-storage fundamentals in 2025 will be consistent with the last two years as there is no obvious catalyst for a sharp acceleration. Self-storage remains a great business long-term, and we are well-positioned to create value through the continued evolution of our operating platform,...

Strong Results Driven by CODI’s Unique Business Model WESTPORT, Conn., Feb. 27, 2025 (GLOBE NEWSWIRE) — Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle market branded consumer and industrial businesses, announced today its consolidated operating results for the three months and full year ended December 31, 2024. “In 2024, we once again delivered strong financial results, achieving double digit sales growth and over 30% growth in our Adjusted EBITDA for the full year,” said Elias Sabo, CEO of Compass Diversified. “In the fourth quarter, we saw both sales and earnings growth accelerate, driven by continued strong performance from our consumer businesses as well as improving performance in our industrial businesses. Our differentiated business model, strong operating companies, and permanent...

Fourth Quarter Pre-Tax Income of $5.9 million and Diluted EPS of $0.23 Full Year 2024 Pre-Tax Income of $173.4 million and Diluted EPS of $8.89 TAMPA, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) — HCI Group, Inc. (NYSE:HCI) reported pre-tax income of $5.9 million and net income of $4.1 million in the fourth quarter of 2024. Net income after noncontrolling interests was $2.6 million compared with $38.1 million in the fourth quarter of 2023. Diluted earnings per share were $0.23 in the fourth quarter of 2024, compared with $3.40 diluted earnings per share, in the fourth quarter of 2023. Adjusted net income (a non-GAAP measure which excludes net unrealized gains or losses on equity securities) for the fourth quarter of 2024 was $5.0 million, or $0.31 diluted earnings per share compared with adjusted net income of $38.8 million, or $3.22...

–  Completed $835 Million in Dispositions in 2024, Surpassing High-End of Increased Guidance –  Reduced Net Debt by $734 million in 2024; Improved Net Debt to Adjusted EBITDA to 7.6x –  Company Meets and Exceeds its Full-Year 2024 Earnings Guidance –  Recently Announced $1.8 Billion Multi-Tenant Portfolio Sale Would Significantly Reduce Leverage and Improve Liquidity Position –  Proposed Transaction Would Create Pure-Play, Single-Tenant Net Lease Company with Enhanced Portfolio Metrics –  Company Initiates Opportunistic $300 Million Share Repurchase Program NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) — Global Net Lease, Inc. (NYSE: GNL) (“GNL” or the “Company”), an internally managed real estate investment trust that focuses on acquiring and managing a globally diversified portfolio of strategically-located commercial real estate...

PALO ALTO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) — HP (NYSE: HPQ)First quarter GAAP diluted net earnings per share (“EPS”) of $0.59, within the previously provided outlook of $0.57 to $0.63 per share First quarter non-GAAP diluted net EPS of $0.74, within the previously provided outlook of $0.70 to $0.76 per share First quarter net revenue of $13.5 billion, up 2.4% from the prior-year period First quarter net cash provided by operating activities of $0.4 billion, free cash flow of $0.1 billion First quarter returned $0.4 billion to shareholders in the form of share repurchases and dividends Estimated $300 million increase in Future Ready plan annualized gross run rate structural cost savings, to $1.9 billion by end of fiscal year 2025 and estimated $150 million increase in restructuring and other charges to approximately...

–  Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25 –  Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update planned for 1H25 –  Petosemtamab evaluation in mCRC ongoing in combination with standard chemotherapy in 1L and 2L and monotherapy in 3L+; mCRC initial clinical data planned for 2H25 –  Based on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our),...

Conference call begins at 4:30 p.m. Eastern time today MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the fourth quarter of 2024 and recent weeks include the following:Enrollment and dosing underway by Merck in the Phase 1 Epstein-Barr virus (EBV) vaccine trial. Dosing of patients has commenced for the Phase I study (NCT06655324) of an EBV vaccine candidate being developed in collaboration with Merck. The investigational vaccine, based on ModeX’s ferritin nanoparticle vaccine platform, is being evaluated for safety and tolerability in up to 200 healthy adults. Commencement of this study triggered a milestone payment to ModeX. Awarded $51 million of additional funding under an existing...

— Record Fourth Quarter Net Sales Rise 4.7 Percent to $1.81 Billion —— Net Sales, Adjusted for Changes in Foreign Currency Rise 7.8 Percent in the 2024 Fourth Quarter —— Gross Profit as a Percentage of Net Sales Improves to 55.5 Percent on a Non-GAAP Adjusted Basis (55.3 Percent on a Reported Basis) in the 2024 Fourth Quarter –— Operating Income Rose 7.9 Percent to $517.9 Million on a Non-GAAP Adjusted Basis —— Net Income Per Diluted Share was $0.38 on a Non-GAAP Adjusted Basis ($0.28 on a Reported Basis) in the 2024 Fourth Quarter — CORONA, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) — Monster Beverage Corporation (NASDAQ: MNST) today reported financial results for the three- and twelve-months ended December 31, 2024. Items Impacting Profitability The tables at the end of this press...